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Blood exchange transfusions were performed in nude rats 
with subcutaneous HTB77 human ovarian carcinoma xeno- 
grafts in an attempt to improve specific monoclonal anti- 
body (MoAb) tumor/non-tumor uptake ratios. Animals 
were injected intravenously with both ‘3’1-5G6.4 specific and 
‘251-UPC-10 non-specific MoAb. Twenty-four hours later 
6580% of the original blood was exchanged with normal 
heparinized rat blood and then these rodents were sacrificed. 
Exchange transfusion significantly (P < 0.05) decreased 
normal tissue activities of “‘I (except for muscle) by 
6385%. while tumor activity decreased only 5%. Tumor to 
background ratios increased from 0.1-0.8 to 2.3-6.3. 
Exchange transfusions substantially enhance tumor/normal 
tissue antibody uptake ratios and, along with plasma- 
pheresis, may be useful in enhancing antibody localization 
in vivo, particularly for therapy. 
Introduction 
Radiolabeled monoclonal antibodies (MoAbs) are gaining 
utility in the diagnosis and treatment of some malignant 
tumors. Diagnostic imaging and therapeutic irradiation 
of tumors are most effective when using the MoAb that 
binds specifically to the target tissue without significant 
non-specific binding to normal tissues or excessive blood 
pool radioactivity. Although MoAbs have specific target 
affinities, such as the murine lgG2ak 566.4 for ovarian 
carcinoma, they also exhibit significant non-specific 
binding in vivo which creates a substantial amount of 
background activity, making imaging and therapy 
difficult. Several approaches have recently been reviewed 
which aim to preserve tumor but reduce background 
activity, but each of these methods is in some sense a 
compromise and the localization of radiolabeled MoAbs 
to tumors remains less than ideal (Goodwin, 1987). 
For example, when antibody fragments are injected, the 
fragment clears from the blood more rapidly than intact 
antibody, thus allowing earlier imaging times and better 
tumor/background ratios, but the absolute radioantibody 
*All correspondence should be addressed to: Richard L. 
Wahl, University of Michigan Medical Center, Nuclear 
Medicine, 1500 E. Medical Center Drive, Ann Arbor, 
MI 48109-0028, U.S.A. 
uptake into the tumor is lower than with intact antibody 
(Wahl et al., 1983). 
In an alternate approach, Wahl et al. (1988a) were able 
to improve tumor/background ratios and enhance gamma 
camera imaging using systemic vascular perfusion with 
saline. Rats injected with 30 PCi t3’I-5G6.4 showed a 
SO-70% drop in normal organ activities following systemic 
perfusion with saline while nude mice treated similarly 
showed a 2.33-fold larger drop in background antibody 
uptake than in the tumor. This approach was conceptually 
related to that described by Begent et al. (1982), in which 
liposomally-entrapped second antibody directed against the 
first antitumor antibody was given. The resulting immune 
complexes then traffic to the spleen and liver for clearance. 
With this approach, increased splenic uptake can occur with 
radioiodinated antibodies and effective clearance of such 
radiometal labeled antibodies is likely not possible. Simi- 
larly, the use of anti-mouse antibodies given after the 
radiolabeled antibody can improve tumor/blood ratios, but 
result in increased targeting of immune complexes to the 
liver and spleen (Goldenberg et al., 1987; Wahl er al., 1987). 
The saline perfusion technique described by Wahl was able 
to improve tumor/non-tumor uptake ratios but it was 
difficult to perform in the mouse and was incompatible with 
life. The current study is an attempt to lower all background 
radioactivity levels without reducing the uptake in the 
tumor, using a more refined approach. Instead of incom- 
plete perfusion with saline in a nude mouse, multiple blood 
exchange transfusion were performed on nude rats with 
subcutaneous HTB77 ovarian carcinomas, a procedure 
compatible with life and similar to plasmapheresis. The 
exchange transfusion technique is simpler to perform in 
rodents, however, and thus was evaluated. This physical 
removal of radioactive blood should remove a significant 
percentage of the non-specifically bound antibody from 
normal tissues, without decreasing the percent bound to the 
tumor, thus improving tumor/background ratios. These 
experiments test the feasibility of this concept. 
Methods 
Monoclonal antibodies 
5G6.4 is an IgG2ak murine MoAb which localizes specifi- 
cally to ovarian cancer xenografts when administered iv. 
(Wahl er al., 1985, 1986b). It was radiolabeled by the 
iodogen method using 1.6 peg Ab: 1 pg iodogen (Wahl er al., 
1988a). The specific activity of the radioantibody injected 
was approx. 17 kCi/pg. The immunoreactivity of the anti- 
body was tested in a direct 1 h cell binding assay (Wahl 
et al., 1990). 
UPC-10 is an IgGZak murine MoAb but is not reactive 
with ovarian carcinoma and was purchased from Bionetics 
(Wahl et al., 1988b, 1989, 1990). It was labeled by the 
iodogen method using approximately the same antibody to 
iodogen ratio as the 566.4 MoAb (Wahl er al., 1987). Its 
specific activity was 8.3 pCi/rg. Free iodine was removed 
from protein bound iodine by anion exchange chroma- 
tography for both reagents. For both antibodies, free iodine 
levels in the preparation were assayed using silica gel thin 
layer chromatography. 
Animal studies 
Female nude rats (N : NIH-mu) from Taconic Farms were 
innoculated with a single cell suspension of 10 million 
HTB77 (human ovarian carcinoma cell line from ATCC) 
cells subcutaneously in the skin over the left shoulder. Four 
to six weeks after injection the rats developed tumors of 
approx. 2 cm in diameter. Before injection with the MoAb 
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mixture the right common carotid artery of experimental 
animals was cannulated with the end of a 7 in. long piece 
of Silastic tubing from Dow Corning (0.020 i.d. x 0.037 in. 
o.d.). The control group was not chronically cannulated. 
This heparinized saline-filled tube was exteriorized through 
the back of the neck and housed in a small stainless steel 
button sewn to the skin to prevent damage by the animal. 
The chronic cannulation technique allowed for easier and 
more replicable vascular access during the transfusions and 
less radiation exposure for the researcher. 
Both control and experimental animals were injected iv. 
into the femoral vein with approx. 80 pCi each of “‘I-5G6.4 
and ‘251-UPC-10 (when possible) in a volume between 0.1 
and 0.5mL. The procedural intensity of the exchange 
transfusions was such that only a limited number of animals 
could be studied per day. Thus, the experiments were 
conducted over several weeks. The animals were housed in 
individual cages and fed standard Purina Laboratory Rat 
Chow and tap water ad libitum. 
Twenty-four hours after antibody injection the blood 
exchange was performed on the experimental group. The 
rats in both groups were anesthetized using 50 mg/kg Pento- 
barbital. Each exchange involved 2 mL of blood being 
removed from the nude rat and replaced with 2 mL of 
heparinized blood collected from normal Sprague-Dawley 
rats. A total of eight transfusions were performed with at 
least 10 min between transfusions, for a total replacement of 
between 65 and 80% of the original blood. This assumes 
total rat blood volume equals 50.0-64.1 mL/kg (Pentel 
et al., 1987; Wang, 1959). Gamma camera imaging was 
performed when possible using a GE400 AT y camera with 
a high energy collimator interfaced to a GE STAR computer 
before and after perfusion. After the final transfusion, all 
the animals were sacrificed and tissue distribution studies 
performed by removing and weighing tissue samples and 
counting them at dual (“‘I and 251) window settings in a 
Packard gamma counter (Wahl et al., 1984). Statistical 
analysis was by unpaired one tail f-test. 
Results 
After technical proficiency was established, the animals 
survived the multiple exchange transfusions well, without 
extra monitoring. The initial control and experimental 
animals received only ‘3’I-5G6.4. “‘I-5G6.4 and ‘251-UPC-I0 
were given to the remainder of the animals. 
The perfusion was reasonably complete, and using y 
camera imaging, whole body drops in “‘I radioactivity of 
40-50% were typical. Radioactivity levels per gram of tissue 
(% kg injected dose/g) at the time of sacrifice are shown in 
Table 1 for 13’1 and in Table 2 for lz51 for both control and 
experimental groups. These show that blood levels 
decreased approx. 80% with perfusion, however. 
Comparison of the tissue biodistribution of activity (a13’I) 
in the control versus the exchange transfused groups shows 
significantly lower values followed perfusion for all tissues 
Table 1. Biodistribution of ‘311-5G6.4 in exchange transfusion vs 
control rats 
Controls (n = 7) 24 h Exchange (n = 5) % Drop in 
Tissue (% kg inj. dose/g) (% kg inj. dose/g) activity (‘)‘I) 
Blood 0.931 * 0.201 0. I95 + 0.073’ 79.0 
S. bowel 0.161 +0.031 0.066 + 0.028’ 59.0 
Ovary 0.271 * 0.049 0.094 + 0.032’ 65.3 
Liver 0.327 + 0.103 0.049 * 0.015’ 
Kidney 0.241 +_ 0.047 0.056 + 0.019’ 
Lung 0.503 +_ 0.103 0.141 i 0.061’ 
Spleen 0.163 + 0.022 0.054 * 0.022’ 
Heart 0.180 i 0.032 0.067 _+ 0.024. 
Muscle 0.143 _+ 0.056 0.093 f 0.073 
Tumor 0.135+0.019 0.128~0.019 








Table 2. Biodistribution of ‘*‘I-UPC-IO in exchange transfusion vs 
control rats 
Controls (n = 6) 24 h Exchange (n = 4) % Drop in 
Tissue (% kg inj. dose/g) (% kg inj. dose/g) activity (“‘I) 
Blood 0.958 i 0.275 0.181 *0.10a* 81.1 
S. bowel 0.161 + 0.041 0.066 * 0.035 59.0 
Ovary 0.271 +_ 0.068 0.094 f 0.041* 65.3 
Liver 0.216 + 0.046 0.049 f 0.015’ 77.3 
Kidney 0.229 _+ 0.054 0.056 + 0.015; 75.5 
Lung 0.522 k 0.126 0.141 f 0.067’ 73.0 
Spleen 0.185 + 0.027 0.054 +_ 0.051 70.8 
Heart 0.189 +_ 0.043 0.067 +_ 0.032’ 64.6 
Muscle 0. I69 + 0.063 0.093 * 0.095 45.0 
Tumor 0.108 + 0.017 0.082 + 0.024 24. I 
*Significantly (P < 0.05) less than control values. 
except muscle and tumor (P c 0.05). The absolute amount 
of activity in the tumor dropped little, 5%, compared with 
the drop in the normal tissues of 63-85% (Table I), thus 
improving tumor/background ratios from 0.1-0.8 to 
2.5-6.3. 
The tissue distribution of ‘25I activity shows significantly 
lower values in the exchange transfused group for the blood, 
ovary, liver, kidney, lung and heart. The small sample size 
may be one reason for the limited difference between the 
exchange transfused group and controls for this antibody 
(‘251-UPC-10). Tumor/blood ratios in the experimental 
group were 1.39 f 0.53 (“‘I-5G6.4, n = 3) and 0.57 + 0.16 
(‘251-UPC-10, n = 3). In the control group the ratios 
were 0.22 k 0.07 ( 13’1-5G6.4, n = 7) and 0.24 rf: 0.13 
(‘251-UPC- 10, n = 5). 
Discussion 
Blood exchange transfusions 24 h post-MoAb injection 
substantially improve tumor/background ratios of specific 
radiolabeled MoAb delivered iv. to rodents with sub- 
cutaneous human ovarian carcinomas. Exchange lowered 
nearly all normal tissue activity without a substantial change 
in the binding to tumor. The drop in blood activity ( 13’1, 
566.4) was greater than 75% and in other tissues (except 
muscle) it was between 63 and 85% while the tumor 
dropped only 5%. This clearly shows that exchange trans- 
fusion can greatly reduce background activity thereby 
improving tumor/background ratios. Such enhancements 
would undoubtedly improve tumor imaging as well as 
enhance specific delivery of the MoAb to its target. This 
lesser decline in normal muscle was also seen when saline 
perfusion was performed and may be due to the relatively 
low vascular volume in muscle. 
Most likely improved tumor/background ratios are 
possible because of specific binding by the MoAb to target 
sites on tumor cells as opposed to non-specific random or 
low affinity associations. Such non-specific interactions are 
more easily disturbed by perfusion with unlabeled blood in 
the normal tissues, whose activity levels dropped after 
exchange transfusion on average of 67% as compared to the 
tumor activity drop of 5%. It is also possible that a 
component of this enhancement effect is due to poor tumor 
vascularity (i.e. it is difficult to get radioantibodies into 
or out of tumors rapidly). It would seem that vascular 
permeability is only a partial contribution, however, because 
of the more rapid clearance of the non-specific antibody 
from the tumor (24% drop) as well as from the normal 
tissues (68% drop). Additional studies in larger animals or 
man could further refine the specifics of the approach, such 
as the ideal time for blood exchange transfusion and the 
duration of the benefit, and the number of times the 
procedure could be performed. 
This study demonstrates that it is possible, using blood 
exchange, to remove a substantial quantity of radioactivity 
from the blood and other normal tissues and improve 
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tumor/background ratios. This improvement has been 
achieved without increasing levels of radioactivity in normal 
tissues such as the liver or spleen as can occur when 
polyclonal antimouse antibodies are used to clear the radio- 
activity (Goldenberg et al., 1987). The remaining questions 
include determining the feasibility of plasmapheresis tech- 
niques (Euler et al., 1985; Charlton et al., 1983) which are 
more applicable to clinical use than blood transfusions 
and whether radionuclide images and therapies improve 
sufficiently as a result of such improved tumor/background 
ratios to justify such an aggressive approach. Nonetheless, 
this exchange transfusion approach, or mimicry of plasma- 
pheresis. may be of value in the treatment of cancer with 
radioantibodies and lays a framework for subsequent 
studies. 
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